AR078886A1 - Estructura co-cristalina del factor d y el anticuerpo anti-factor d util pa-ra diagnostico, profilaxis y tratamiento de enfermedades - Google Patents
Estructura co-cristalina del factor d y el anticuerpo anti-factor d util pa-ra diagnostico, profilaxis y tratamiento de enfermedadesInfo
- Publication number
- AR078886A1 AR078886A1 ARP100104082A ARP100104082A AR078886A1 AR 078886 A1 AR078886 A1 AR 078886A1 AR P100104082 A ARP100104082 A AR P100104082A AR P100104082 A ARP100104082 A AR P100104082A AR 078886 A1 AR078886 A1 AR 078886A1
- Authority
- AR
- Argentina
- Prior art keywords
- factor
- amino acid
- seq
- acid residues
- machine
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 125000000539 amino acid group Chemical group 0.000 abstract 3
- 150000005829 chemical entities Chemical class 0.000 abstract 3
- 239000001648 tannin Substances 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 238000013500 data storage Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000011232 storage material Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28046009P | 2009-11-04 | 2009-11-04 | |
| US28171609P | 2009-11-20 | 2009-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078886A1 true AR078886A1 (es) | 2011-12-07 |
Family
ID=43303899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104082A AR078886A1 (es) | 2009-11-04 | 2010-11-04 | Estructura co-cristalina del factor d y el anticuerpo anti-factor d util pa-ra diagnostico, profilaxis y tratamiento de enfermedades |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110165648A1 (enExample) |
| EP (1) | EP2496695A1 (enExample) |
| JP (1) | JP2013509866A (enExample) |
| KR (1) | KR20120120153A (enExample) |
| CN (1) | CN102666850A (enExample) |
| AR (1) | AR078886A1 (enExample) |
| BR (1) | BR112012011607A2 (enExample) |
| CA (1) | CA2782481A1 (enExample) |
| IN (1) | IN2012DN03338A (enExample) |
| MX (1) | MX2012005430A (enExample) |
| RU (1) | RU2012122700A (enExample) |
| TW (1) | TW201121993A (enExample) |
| WO (1) | WO2011057014A1 (enExample) |
| ZA (1) | ZA201202602B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
| US10093978B2 (en) | 2013-08-12 | 2018-10-09 | Genentech, Inc. | Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms |
| EP3041513B1 (en) | 2013-09-08 | 2020-08-05 | Kodiak Sciences Inc. | Factor viii zwitterionic polymer conjugates |
| AU2015253042A1 (en) | 2014-05-01 | 2016-10-20 | Genentech, Inc. | Anti-factor D antibody variants and uses thereof |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CN107208076A (zh) | 2014-10-17 | 2017-09-26 | 科达制药 | 丁酰胆碱酯酶两性离子聚合物缀合物 |
| JP2018536650A (ja) | 2015-10-30 | 2018-12-13 | ジェネンテック， インコーポレイテッド | 抗ｄ因子抗体変異体コンジュゲート及びその使用 |
| US10407510B2 (en) | 2015-10-30 | 2019-09-10 | Genentech, Inc. | Anti-factor D antibodies and conjugates |
| CA3003647A1 (en) * | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibody formulations |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| CA3011819A1 (en) * | 2016-01-20 | 2017-07-27 | Vitrisa Therapeutics, Inc. | Compositions and methods for inhibiting factor d |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| CA3059938A1 (en) * | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
| US6291161B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertiore |
| CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| US6291160B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| US6291159B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| AU638762B2 (en) | 1989-10-05 | 1993-07-08 | Optein Inc | Cell-free synthesis and isolation of novel genes and polypeptides |
| US5244800A (en) * | 1990-04-27 | 1993-09-14 | The Uab Research Foundation | Crystals of human complement factor d that are triclinic |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US6956107B2 (en) | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
| JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック， インコーポレイテッド | 合成抗体ファージライブラリー |
| KR20140101873A (ko) * | 2006-11-02 | 2014-08-20 | 제넨테크, 인크. | 인간화 항-ｄ 인자 항체 |
| AR066660A1 (es) * | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| CR20170001A (es) * | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
-
2010
- 2010-11-03 US US12/927,009 patent/US20110165648A1/en not_active Abandoned
- 2010-11-04 CN CN2010800568895A patent/CN102666850A/zh active Pending
- 2010-11-04 BR BR112012011607-0A patent/BR112012011607A2/pt not_active Application Discontinuation
- 2010-11-04 JP JP2012537229A patent/JP2013509866A/ja active Pending
- 2010-11-04 TW TW099137982A patent/TW201121993A/zh unknown
- 2010-11-04 KR KR1020127014237A patent/KR20120120153A/ko not_active Withdrawn
- 2010-11-04 AR ARP100104082A patent/AR078886A1/es unknown
- 2010-11-04 WO PCT/US2010/055509 patent/WO2011057014A1/en not_active Ceased
- 2010-11-04 RU RU2012122700/10A patent/RU2012122700A/ru not_active Application Discontinuation
- 2010-11-04 EP EP10774413A patent/EP2496695A1/en not_active Withdrawn
- 2010-11-04 IN IN3338DEN2012 patent/IN2012DN03338A/en unknown
- 2010-11-04 MX MX2012005430A patent/MX2012005430A/es not_active Application Discontinuation
- 2010-11-04 CA CA2782481A patent/CA2782481A1/en not_active Abandoned
-
2012
- 2012-04-11 ZA ZA2012/02602A patent/ZA201202602B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2782481A1 (en) | 2011-05-12 |
| TW201121993A (en) | 2011-07-01 |
| BR112012011607A2 (pt) | 2020-06-02 |
| EP2496695A1 (en) | 2012-09-12 |
| ZA201202602B (en) | 2013-06-26 |
| IN2012DN03338A (enExample) | 2015-10-23 |
| MX2012005430A (es) | 2012-06-19 |
| RU2012122700A (ru) | 2013-12-10 |
| US20110165648A1 (en) | 2011-07-07 |
| KR20120120153A (ko) | 2012-11-01 |
| WO2011057014A1 (en) | 2011-05-12 |
| CN102666850A (zh) | 2012-09-12 |
| JP2013509866A (ja) | 2013-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078886A1 (es) | Estructura co-cristalina del factor d y el anticuerpo anti-factor d util pa-ra diagnostico, profilaxis y tratamiento de enfermedades | |
| ES2602971T3 (es) | Composición de anticuerpo modificado | |
| Fry et al. | Novel transcripts in the maxillary venom glands of advanced snakes | |
| McVeigh et al. | Fasciola hepatica virulence-associated cysteine peptidases: a systems biology perspective | |
| JP2014224134A5 (enExample) | ||
| PE20110802A1 (es) | Un anticuerpo antagonista de pcsk9 | |
| Mulenga et al. | A mblyomma americanum tick saliva serine protease inhibitor 6 is a cross‐class inhibitor of serine proteases and papain‐like cysteine proteases that delays plasma clotting and inhibits platelet aggregation | |
| CL2008003089A1 (es) | Metodo para tratar enfermedad de alzheimer que comprende un regimen de un anticuerpo que se un epitopo en el n-terminal del peptido amiloide beta, anticuerpo humanizado contra la proteina amiloide beta que tiene sustituidas las posiciones 234, 235, y 237 por alanina en la region constante de las cadenas pesadas. | |
| PE20141660A1 (es) | PROTEINAS DE UNION A ANTIGENO DE TNF-ALFA CON UNION A FcRn INCREMENTADA | |
| PE20212075A1 (es) | PROTEINAS DE FUSION Fc IL-22 Y METODOS DE USO | |
| CR9576A (es) | METODOS PARA PURIFICAR PROTEINAS QUE CONTIENE LA REGION Fc | |
| EA201290722A1 (ru) | Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение | |
| HRP20150807T1 (hr) | PRIPRAVCI KOJI SADRŽE PROTUTIJELO, ILI NJEGOV FRAGMENT, SPECIFIÄŚNO ZA aP2, NAMIJENJENO UPOTREBI U LIJEÄŚENJU DIJABETESA, NEPODNOŠENJA GLUKOZE ILI OTPORNOSTI NA INZULIN UZROKOVANE PRETILOŠÄ†U | |
| NO20054953L (no) | Fremgangsmate og program for rekonstruksjon av frakturplan | |
| BR112012010252A2 (pt) | variantes de glicosilação de anticorpo | |
| JP2016536315A5 (enExample) | ||
| KR20240121879A (ko) | Mhc-펩타이드 타겟에 결합하는 항원 인식 분자에 대한 오프 타겟 예측 방법 | |
| MX343630B (es) | Medios y metodos para diagnosticar y tratar esclerosis multiple. | |
| Tan et al. | Sharp-nosed Pit Viper (Deinagkistrodon acutus) from Taiwan and China: A comparative study on venom toxicity and neutralization by two specific antivenoms across the Strait | |
| Parkinson et al. | Development of an acid challenge-based in vitro dentin disc occlusion model. | |
| Zhang et al. | Enzyme activity of Schistosoma japonicum cercarial elastase SjCE-2b ascertained by in vitro refolded recombinant protein | |
| ATE551067T1 (de) | Tumstatin zur behandlung von erkrankungen die mit der neumodellierung von atemwegsgewebe zusammenhängen | |
| Bafwafwa et al. | Risk factors affecting mortality in children with pulmonary tuberculosis in lubumbashi, democratic republic of the Congo | |
| Saavedra et al. | Natural snake venom inhibitors and their pharmaceutical uses: challenges and possibilities | |
| Robbins et al. | Macromolecules from living and fossil biominerals: Implications for the establishment of molecular phylogenies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |